Luca Issi
Stock Analyst at RBC Capital
(0.97)
# 3,597
Out of 4,754 analysts
187
Total ratings
25.44%
Success rate
-18.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $26 → $25 | $24.35 | +2.67% | 5 | Mar 3, 2025 | |
| BEAM Beam Therapeutics | Maintains: Sector Perform | $24 → $26 | $26.17 | -0.65% | 7 | Feb 26, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $310 | $241.98 | +28.11% | 26 | Feb 26, 2025 | |
| IONS Ionis Pharmaceuticals | Reiterates: Outperform | $70 | $32.97 | +112.31% | 8 | Feb 20, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Sector Perform | $70 | $70.59 | -0.83% | 12 | Feb 20, 2025 | |
| MRNA Moderna | Reiterates: Sector Perform | $40 | $30.88 | +29.53% | 13 | Feb 18, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Sector Perform | $53 → $48 | $43.67 | +9.91% | 13 | Feb 12, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Outperform | $42 | $18.08 | +132.37% | 8 | Feb 11, 2025 | |
| QURE uniQure | Reiterates: Outperform | $24 | $12.10 | +98.43% | 6 | Jan 21, 2025 | |
| SLB Schlumberger | Reiterates: Outperform | $57 | $41.41 | +37.66% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $6.37 | +370.96% | 9 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $24 | $2.65 | +807.37% | 4 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $67 | $29.35 | +128.28% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $45 | $12.69 | +254.61% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $1.81 | +121.61% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $80 | $3.95 | +1,925.32% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $11 | $6.90 | +59.42% | 5 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $39 | $4.48 | +771.51% | 6 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $42.04 | +83.16% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $6.21 | +173.75% | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $10 | $4.70 | +112.99% | 6 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $15 | $10.45 | +43.54% | 5 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $95 → $105 | $23.82 | +340.81% | 6 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $54 | $9.95 | +442.99% | 4 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.15 | +1,122.71% | 5 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.86 | +439.08% | 7 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 | $0.96 | +109.29% | 5 | Mar 14, 2024 |
Apellis Pharmaceuticals
Mar 3, 2025
Maintains: Sector Perform
Price Target: $26 → $25
Current: $24.35
Upside: +2.67%
Beam Therapeutics
Feb 26, 2025
Maintains: Sector Perform
Price Target: $24 → $26
Current: $26.17
Upside: -0.65%
Alnylam Pharmaceuticals
Feb 26, 2025
Reiterates: Outperform
Price Target: $310
Current: $241.98
Upside: +28.11%
Ionis Pharmaceuticals
Feb 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $32.97
Upside: +112.31%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $70.59
Upside: -0.83%
Moderna
Feb 18, 2025
Reiterates: Sector Perform
Price Target: $40
Current: $30.88
Upside: +29.53%
CRISPR Therapeutics AG
Feb 12, 2025
Maintains: Sector Perform
Price Target: $53 → $48
Current: $43.67
Upside: +9.91%
Arrowhead Pharmaceuticals
Feb 11, 2025
Reiterates: Outperform
Price Target: $42
Current: $18.08
Upside: +132.37%
uniQure
Jan 21, 2025
Reiterates: Outperform
Price Target: $24
Current: $12.10
Upside: +98.43%
Schlumberger
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $41.41
Upside: +37.66%
Jan 21, 2025
Reiterates: Outperform
Price Target: $30
Current: $6.37
Upside: +370.96%
Jan 21, 2025
Reiterates: Outperform
Price Target: $24
Current: $2.65
Upside: +807.37%
Jan 21, 2025
Reiterates: Outperform
Price Target: $67
Current: $29.35
Upside: +128.28%
Jan 14, 2025
Reiterates: Outperform
Price Target: $45
Current: $12.69
Upside: +254.61%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $1.81
Upside: +121.61%
Nov 15, 2024
Reiterates: Sector Perform
Price Target: $80
Current: $3.95
Upside: +1,925.32%
Nov 14, 2024
Maintains: Outperform
Price Target: $9 → $11
Current: $6.90
Upside: +59.42%
Nov 14, 2024
Maintains: Outperform
Price Target: $40 → $39
Current: $4.48
Upside: +771.51%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $42.04
Upside: +83.16%
Nov 6, 2024
Maintains: Outperform
Price Target: $20 → $17
Current: $6.21
Upside: +173.75%
Nov 5, 2024
Maintains: Sector Perform
Price Target: $12 → $10
Current: $4.70
Upside: +112.99%
Oct 21, 2024
Maintains: Sector Perform
Price Target: $7 → $15
Current: $10.45
Upside: +43.54%
Oct 21, 2024
Maintains: Outperform
Price Target: $95 → $105
Current: $23.82
Upside: +340.81%
Sep 19, 2024
Reiterates: Outperform
Price Target: $54
Current: $9.95
Upside: +442.99%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $1.15
Upside: +1,122.71%
Mar 15, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.86
Upside: +439.08%
Mar 14, 2024
Reiterates: Sector Perform
Price Target: $2
Current: $0.96
Upside: +109.29%